Analyst Ratings January 28, 2026

Raymond James Lifts First BanCorp Price Target to $26, Keeps Outperform Rating

Analyst boost follows strong quarter and continued net interest margin expansion at the Puerto Rico-based lender

By Ajmal Hussain FBP
Raymond James Lifts First BanCorp Price Target to $26, Keeps Outperform Rating
FBP

Raymond James raised its price target on First BanCorp (NYSE:FBP) to $26.00 from $25.00 and left its Outperform rating intact, citing robust fourth-quarter results driven by ongoing net interest margin (NIM) expansion. The firm pointed to favorable drivers including securities repricing, lower funding costs, and solid loan pipelines, while noting the stock trades below midcap peers on a 2026 earnings multiple basis.

Key Points

  • Raymond James raised its First BanCorp price target to $26.00 from $25.00 and retained an Outperform rating.
  • The firm attributed the move to strong 4Q25 results led by continued net interest margin expansion, plus benefits from securities repricing and lower funding costs; C&I and residential real estate pipelines support loan growth.
  • Raymond James highlighted First BanCorp’s 100% capital return and 18% ROTCE, while noting shares trade at 10.2x 2026 earnings versus midcap peers at 11.4x.

Raymond James has increased its price target on First BanCorp to $26.00 from $25.00 and maintained an Outperform rating on the shares. The change follows what the firm characterized as "strong 4Q25 results driven by continued NIM expansion" at the Puerto Rico-based bank.

In its update, Raymond James said First BanCorp should continue to realize benefits from securities repricing and lower funding costs, both of which support margin improvement. The firm also highlighted the bank's commercial and industrial (C&I) and residential real estate pipelines as underlying contributors to projected loan growth.

Another factor Raymond James emphasized is the company's capital return policy. The analyst noted First BanCorp's 100% capital return as a "material tailwind" for the stock and underlined the bank's 18% return on tangible common equity (ROTCE) as a measure of profitability.

Raymond James additionally pointed to an "attractive macroeconomic backdrop given reshoring investments in Puerto Rico," framing the island's investment environment as supportive of the lender's outlook. On valuation, the firm observed that First BanCorp's shares are trading at 10.2x its 2026 earnings estimate, versus midcap peers at 11.4x.


Analysis

The upgrade to the target price is modest in absolute terms but reflects the analyst view that recent operational trends - notably NIM expansion and lower funding costs - have improved near-term earnings visibility. Loan growth driven by C&I and residential real estate activity is presented as a tangible pipeline that should sustain balance-sheet momentum, while the full capital-return stance is called out as a direct positive for shareholder value.

The valuation differential to midcap peers is highlighted by Raymond James, suggesting the stock currently trades at a discount to comparable companies on a 2026 earnings multiple basis.


What this means for markets

  • The update underscores dynamics in regional banking and Puerto Rico's financial ecosystem, with potential implications for lenders exposed to local economic trends.
  • Debt and securities markets matter here - securities repricing and funding-cost trends are central to the analyst case.
  • Real estate and commercial lending pipelines are important drivers for loan growth and bank earnings.

Risks

  • If net interest margin expansion or lower funding costs reverse, projected earnings improvements could be undermined - this primarily affects the banking and financial sectors.
  • Slower-than-expected loan origination in commercial and industrial or residential real estate pipelines would weaken the loan growth outlook and impact regional lenders and real estate markets.
  • Valuation risk as the stock trades at a lower multiple (10.2x) versus midcap peers (11.4x); relative valuation could limit near-term upside if peer multiples re-rate.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026